First Clinical Study of the Selective 5‐HT3 Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache

E. G.M. Couturier; R. Hering; C. A. Foster; T. J. Steiner; F. Clifford Rose

doi:10.1111/j.1526-4610.1991.hed3105296.x

First Clinical Study of the Selective 5‐HT₃ Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache

E. G.M. Couturier^*, R. Hering, C. A. Foster, T. J. Steiner, F. Clifford Rose

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

SYNOPSISGranisetron (BRL 43694), a selective 5‐HT₃ receptor antagonist, was assessed as acute therapy for the first time in migraine patients. In an open pilot study 7 migraine attacks were treated in 6 patients. All but I patient experienced marked and rapid relief from the headache, and nausea and vomiting were rapidly resolved in the 6 cases where these symptoms accompanied the attack. No side effects were recorded. Development of granisetron for migraine was suspended during the study for extraneous reasons.

Original language	English
Pages (from-to)	296-297
Number of pages	2
Journal	Headache: The Journal of Head and Face Pain
Volume	31
Issue number	5
DOIs	https://doi.org/10.1111/j.1526-4610.1991.hed3105296.x
Publication status	Published - 1 Jan 1991
Externally published	Yes

Access to Document

10.1111/j.1526-4610.1991.hed3105296.x

Cite this

@article{2879f499304a4b93a9d86bbc31f5f361,

title = "First Clinical Study of the Selective 5‐HT3 Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache",

abstract = "SYNOPSISGranisetron (BRL 43694), a selective 5‐HT3 receptor antagonist, was assessed as acute therapy for the first time in migraine patients. In an open pilot study 7 migraine attacks were treated in 6 patients. All but I patient experienced marked and rapid relief from the headache, and nausea and vomiting were rapidly resolved in the 6 cases where these symptoms accompanied the attack. No side effects were recorded. Development of granisetron for migraine was suspended during the study for extraneous reasons.",

keywords = "5‐HT, acute migraine, granisetron, serotonin",

author = "Couturier, {E. G.M.} and R. Hering and Foster, {C. A.} and Steiner, {T. J.} and Rose, {F. Clifford}",

year = "1991",

month = jan,

day = "1",

doi = "10.1111/j.1526-4610.1991.hed3105296.x",

language = "English",

volume = "31",

pages = "296--297",

journal = "Headache",

issn = "0017-8748",

publisher = "Wiley-Blackwell",

number = "5",

}

First Clinical Study of the Selective 5‐HT₃ Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache. / Couturier, E. G.M.; Hering, R.; Foster, C. A.; Steiner, T. J.; Rose, F. Clifford.

In: Headache: The Journal of Head and Face Pain, Vol. 31, No. 5, 01.01.1991, p. 296-297.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - First Clinical Study of the Selective 5‐HT3 Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache

AU - Couturier, E. G.M.

AU - Hering, R.

AU - Foster, C. A.

AU - Steiner, T. J.

AU - Rose, F. Clifford

PY - 1991/1/1

Y1 - 1991/1/1

N2 - SYNOPSISGranisetron (BRL 43694), a selective 5‐HT3 receptor antagonist, was assessed as acute therapy for the first time in migraine patients. In an open pilot study 7 migraine attacks were treated in 6 patients. All but I patient experienced marked and rapid relief from the headache, and nausea and vomiting were rapidly resolved in the 6 cases where these symptoms accompanied the attack. No side effects were recorded. Development of granisetron for migraine was suspended during the study for extraneous reasons.

AB - SYNOPSISGranisetron (BRL 43694), a selective 5‐HT3 receptor antagonist, was assessed as acute therapy for the first time in migraine patients. In an open pilot study 7 migraine attacks were treated in 6 patients. All but I patient experienced marked and rapid relief from the headache, and nausea and vomiting were rapidly resolved in the 6 cases where these symptoms accompanied the attack. No side effects were recorded. Development of granisetron for migraine was suspended during the study for extraneous reasons.

KW - 5‐HT

KW - acute migraine

KW - granisetron

KW - serotonin

UR - http://www.scopus.com/inward/record.url?scp=0025739778&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4610.1991.hed3105296.x

DO - 10.1111/j.1526-4610.1991.hed3105296.x

M3 - Article

C2 - 1650335

AN - SCOPUS:0025739778

VL - 31

SP - 296

EP - 297

JO - Headache

JF - Headache

SN - 0017-8748

IS - 5

ER -

First Clinical Study of the Selective 5‐HT3 Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache

Abstract

Access to Document

Other files and links

Cite this

First Clinical Study of the Selective 5‐HT₃ Antagonist, Granisetron (BRL 43694), in the Acute Treatment of Migraine Headache